Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Corey

Showing results (361-370 of 551) with videos related to

Pageof 56
Sort By:
Vaccine|October 7, 2025
Safety and immunogenicity of investigational herpes simplex virus-2 vaccines in adults with recurrent genital infectionKerry J Laing, Anton M Sholukh, Kellie J MacPhee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 17, 2023
Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentationBrandon Cieniewicz, Ankit Bhatta, Damoun Torabi, et al.
Frontiers in Immunology|December 13, 2019
Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector CellsLeigh Fisher, Melissa Zinter, Sherry Stanfield-Oakley, et al.
The Journal of Infectious Diseases|August 1, 2013
Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trialAndrew Mujugira, Amalia S Magaret, Connie Celum, et al.
Viruses|October 26, 2021
Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 TransmissionDavid A Swan, Ashish Goyal, Chloe Bracis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 17, 2022
Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine TrialKwabena Asare, Tsion Andine, Nivashnee Naicker, et al.
Lancet (London, England)|February 28, 2004
Dual HIV-1 infection associated with rapid disease progressionGeoffrey S Gottlieb, David C Nickle, Mark A Jensen, et al.
Plos Medicine|August 15, 2008
The use of nonhuman primate models in HIV vaccine developmentCecilia Morgan, Marta Marthas, Christopher Miller, et al.
NPJ Vaccines|September 20, 2022
KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccineCorey Casper, Lawrence Corey, Jeffrey I Cohen, et al.
Plos One|September 15, 2015
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated MenZoe Moodie, Barbara Metch, Linda-Gail Bekker, et al.
Pageof 56

Showing results (361-370 of 551) with videos related to

Sort By:
Pageof 56
Vaccine|October 7, 2025
Safety and immunogenicity of investigational herpes simplex virus-2 vaccines in adults with recurrent genital infectionKerry J Laing, Anton M Sholukh, Kellie J MacPhee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 17, 2023
Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentationBrandon Cieniewicz, Ankit Bhatta, Damoun Torabi, et al.
Frontiers in Immunology|December 13, 2019
Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector CellsLeigh Fisher, Melissa Zinter, Sherry Stanfield-Oakley, et al.
The Journal of Infectious Diseases|August 1, 2013
Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trialAndrew Mujugira, Amalia S Magaret, Connie Celum, et al.
Viruses|October 26, 2021
Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 TransmissionDavid A Swan, Ashish Goyal, Chloe Bracis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 17, 2022
Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine TrialKwabena Asare, Tsion Andine, Nivashnee Naicker, et al.
Lancet (London, England)|February 28, 2004
Dual HIV-1 infection associated with rapid disease progressionGeoffrey S Gottlieb, David C Nickle, Mark A Jensen, et al.
Plos Medicine|August 15, 2008
The use of nonhuman primate models in HIV vaccine developmentCecilia Morgan, Marta Marthas, Christopher Miller, et al.
NPJ Vaccines|September 20, 2022
KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccineCorey Casper, Lawrence Corey, Jeffrey I Cohen, et al.
Plos One|September 15, 2015
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated MenZoe Moodie, Barbara Metch, Linda-Gail Bekker, et al.
Pageof 56